Was the UNITED THERAPEUTICS (UTHR) CFO’s share sale pre-planned under a Rule 10b5-1 plan?

Yes. A footnote states the option exercise and subsequent sale were executed under a Rule 10b5-1 trading plan. That plan was entered into on October 31, 2025, indicating the timing of these trades was scheduled in advance rather than decided on the trade date.

UNITED THERAPEUTICS (UTHR) CFO exercises 10K options, sells 10K shares

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

UNITED THERAPEUTICS Corp Chief Financial Officer and Treasurer James Edgemond reported an exercise-and-sell transaction in company stock. On May 4, 2026, he exercised stock options to acquire 10,000 shares of common stock at a strike price of $135.42 per share and sold 10,000 shares in multiple open-market trades at prices generally between the high $560s and low $580s per share. The filing states these trades were carried out under a pre-arranged Rule 10b5-1 trading plan entered into on October 31, 2025, indicating the timing was scheduled in advance. After the transactions, Edgemond continues to hold 28,876 shares of common stock directly, along with 32,500 stock options, signaling he retains a meaningful equity stake in UNITED THERAPEUTICS.

Insider Trade Summary 10b5-1

Net Seller: 10,000 shares ($5,769,338)

Net Sell 15 txns

Insider EDGEMOND JAMES

Role CFO AND TREASURER

Sold 10,000 shs ($5.77M)

Type	Security	Shares	Price	Value
Exercise	Stock Option	10,000	$0.00	--
Exercise	Common Stock	10,000	$135.42	$1.35M
Sale	Common Stock	80	$568.6047	$45K
Sale	Common Stock	80	$570.06	$46K
Sale	Common Stock	40	$570.9975	$23K
Sale	Common Stock	480	$572.3967	$275K
Sale	Common Stock	153	$573.8217	$88K
Sale	Common Stock	487	$574.8441	$280K
Sale	Common Stock	2,436	$575.7487	$1.40M
Sale	Common Stock	3,005	$576.6573	$1.73M
Sale	Common Stock	719	$577.5406	$415K
Sale	Common Stock	1,160	$579.1252	$672K
Sale	Common Stock	440	$580.2561	$255K
Sale	Common Stock	520	$581.2808	$302K
Sale	Common Stock	400	$582.289	$233K

Holdings After Transaction: Stock Option — 32,500 shares (Direct, null); Common Stock — 28,876 shares (Direct, null)

Footnotes (1)

This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. This transaction was executed in multiple trades at prices ranging from $577.31 to $577.94. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $578.72 to $579.40. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $579.86 to $580.53. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $581.06 to $582.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $582.06 to $582.75. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $568.355 to $568.85. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $569.61 to $570.51. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $570.84 to $571.29. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $572.06 to $573.02. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $573.14 to $574.12. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $574.22 to $575.21. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $575.24 to $576.235. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $576.26 to $577.22. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Key Figures

Shares sold: 10,000 shares Sale price range: $568–$582/share Options exercised: 10,000 shares +5 more

8 metrics

Shares sold 10,000 shares Common stock open-market sales on May 4, 2026

Sale price range $568–$582/share Weighted-average prices across multiple trades

Options exercised 10,000 shares Stock option exercise into common stock

Option strike price $135.42/share Exercise price for 10,000 stock options

Shares held after 28,876 shares Direct common stock ownership after transactions

Options held after 32,500 options Stock options outstanding after reported exercise

Net buy/sell shares -10,000 shares Transaction summary net-sell direction

Derivative exercise count 1 transaction Exercise or conversion of derivative security

Key Terms

Rule 10b5-1 trading plan, stock options, open-market sale, exercise or conversion of derivative security, +2 more

6 terms

Rule 10b5-1 trading plan regulatory

"exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

stock options financial

"This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

exercise or conversion of derivative security financial

"transaction_code_description": "Exercise or conversion of derivative security""

weighted average price financial

"The price reported above reflects the weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

multiple trades financial

"This transaction was executed in multiple trades at prices ranging from"

Form 4 Insider Transactions: What Each Field Means →

05/05/2026 - 04:30 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

EDGEMOND JAMES

(Last)

(First)

(Middle)

C/O UNITED THERAPEUTICS CORPORATION

1000 SPRING STREET

(Street)

SILVER SPRING

MARYLAND

20910

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CFO AND TREASURER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/04/2026		M⁽¹⁾		10,000	A	$135.42	28,876	D
Common Stock	05/04/2026		S⁽¹⁾		80	D	$568.6047⁽²⁾	28,796	D
Common Stock	05/04/2026		S⁽¹⁾		80	D	$570.06⁽³⁾	28,716	D
Common Stock	05/04/2026		S⁽¹⁾		40	D	$570.9975⁽⁴⁾	28,676	D
Common Stock	05/04/2026		S⁽¹⁾		480	D	$572.3967⁽⁵⁾	28,196	D
Common Stock	05/04/2026		S⁽¹⁾		153	D	$573.8217⁽⁶⁾	28,043	D
Common Stock	05/04/2026		S⁽¹⁾		487	D	$574.8441⁽⁷⁾	27,556	D
Common Stock	05/04/2026		S⁽¹⁾		2,436	D	$575.7487⁽⁸⁾	25,120	D
Common Stock	05/04/2026		S⁽¹⁾		3,005	D	$576.6573⁽⁹⁾	22,115	D
Common Stock	05/04/2026		S⁽¹⁾		719	D	$577.5406⁽¹⁰⁾	21,396	D
Common Stock	05/04/2026		S⁽¹⁾		1,160	D	$579.1252⁽¹¹⁾	20,236	D
Common Stock	05/04/2026		S⁽¹⁾		440	D	$580.2561⁽¹²⁾	19,796	D
Common Stock	05/04/2026		S⁽¹⁾		520	D	$581.2808⁽¹³⁾	19,276	D
Common Stock	05/04/2026		S⁽¹⁾		400	D	$582.289⁽¹⁴⁾	18,876	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option	$135.42	05/04/2026		M⁽¹⁾			10,000	03/15/2023	03/15/2027	Common Stock	10,000	$0.00	32,500	D

Explanation of Responses:

1. This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025.

2. This transaction was executed in multiple trades at prices ranging from $568.355 to $568.85. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

3. This transaction was executed in multiple trades at prices ranging from $569.61 to $570.51. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

4. This transaction was executed in multiple trades at prices ranging from $570.84 to $571.29. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

5. This transaction was executed in multiple trades at prices ranging from $572.06 to $573.02. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

6. This transaction was executed in multiple trades at prices ranging from $573.14 to $574.12. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

7. This transaction was executed in multiple trades at prices ranging from $574.22 to $575.21. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

8. This transaction was executed in multiple trades at prices ranging from $575.24 to $576.235. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

9. This transaction was executed in multiple trades at prices ranging from $576.26 to $577.22. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

10. This transaction was executed in multiple trades at prices ranging from $577.31 to $577.94. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

11. This transaction was executed in multiple trades at prices ranging from $578.72 to $579.40. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

12. This transaction was executed in multiple trades at prices ranging from $579.86 to $580.53. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

13. This transaction was executed in multiple trades at prices ranging from $581.06 to $582.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

14. This transaction was executed in multiple trades at prices ranging from $582.06 to $582.75. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

	/s/ John S. Hess, Jr. under Power of Attorney	05/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did UNITED THERAPEUTICS (UTHR) CFO James Edgemond do in this Form 4 filing?

CFO James Edgemond exercised options for 10,000 UNITED THERAPEUTICS shares and sold 10,000 shares in the open market. These transactions were reported as part of a routine insider filing and were executed under a pre-arranged Rule 10b5-1 trading plan.

How many UNITED THERAPEUTICS (UTHR) shares did the CFO sell and at what prices?

James Edgemond sold 10,000 UNITED THERAPEUTICS common shares in multiple open-market trades. Reported weighted-average prices for individual trades ranged from about $568 to more than $582 per share, reflecting execution across a narrow price band on May 4, 2026.

What stock options did the UNITED THERAPEUTICS (UTHR) CFO exercise in this transaction?

The CFO exercised stock options covering 10,000 UNITED THERAPEUTICS common shares at a strike price of $135.42 per share. These options had an original exercise date in March 2023 and an expiration date in March 2027, according to the Form 4 data.

How many UNITED THERAPEUTICS (UTHR) shares does the CFO hold after these trades?

After the reported transactions, CFO James Edgemond directly holds 28,876 UNITED THERAPEUTICS common shares. The filing also shows he holds 32,500 stock options, providing ongoing equity exposure alongside his remaining direct share ownership in the company.

What is the net effect of the UNITED THERAPEUTICS (UTHR) CFO’s Form 4 transactions?

The net effect is an exercise-and-sell pattern: he exercised options for 10,000 shares and sold 10,000 shares in the market. The transaction summary shows 10,000 shares sold and 10,000 shares exercised, resulting in a net-sell direction for reported buy/sell activity.